Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 3Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Gliosarcoma 1Glioma 1Glioblastoma 1Enteropathy-Associated T-Cell Lymphoma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 11Rituximab 6Prednisone 6fludarabine 5Vincristine 5Doxorubicin 5Etoposide 4fludarabine phosphate 3Bortezomib 3Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2MLN 8237 2Electrocardiography 2Echocardiography 2Diphenhydramine 2CT-P10 2Automobiles 2Acetaminophen 2venetoclax 1varlilumab 1tositumomab I-131 1tazemetostat 1saponin QA-21V1 1romidepsin 1pomalidomide 1obinutuzumab 1molibresib 1magrolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Lymphoma, B-Cell × Automobiles × Clear all
NCT02659943 2023-04-19

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
27 enrolled 25 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT04160195 2022-02-15

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
2 enrolled 14 charts
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡